Key Highlights

  • 614.25 is the odd per-share loss estimate listed in the snapshot for Jaguar Health, compared with losses of 0.57 at Tvardi, 0.37 at Vistagen and 0.11 at Biofrontera, a discrepancy marked as unexplained.
  • 6.44 million is the USD valuation of Jaguar Health in the snapshot, under USD 8.33 million at Vistagen, USD 13.92 million at Biofrontera and USD 17.87 million at Tvardi, all at nano-cap scale.
  • 31.7 million is the USD Vistagen held in cash plus marketable securities on June 30, 2026, against USD 15.8 million in cash at Tvardi and USD 4.7 million at Biofrontera, while no Jaguar Health cash figure turned up.
  • 22.1 million is the USD in product sales Biofrontera booked over six months, up 25.4%, compared with USD 1.48 million in quarterly Revenue at Vistagen and USD 1.225 million at Jaguar Health for the latest quarter.

Tvardi Therapeutics, Inc. (NASDAQ:TVRD): Estimate 0.57 and a Shrinking Loss

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) is slated to publish third quarter 2026 results ahead of the opening bell on November 13, 2026. Analysts project a loss of 0.57 a share, and the screener snapshot lists a valuation of USD 17.87 million, a nano-cap size that brings sharp Volatility and trading risk. Last quarter's loss was USD 0.69 a share while the loss over six months was USD 1.41 a share, so the forecast implies a smaller loss. Taken together, the figures show a narrowing loss alongside a shrinking cash balance. R&D came to USD 4.0 million compared with USD 5.8 million, G&A was USD 2.6 million compared with USD 3.1 million, and overall operating costs were USD 6.6 million compared with USD 8.9 million. Tvardi Therapeutics, Inc. (NASDAQ:TVRD) had USD 15.8 million in cash, down from USD 30.8 million, with management saying the money lasts through the topline readout for TTI-101 in hepatocellular carcinoma, due in fourth-quarter 2026, and into third-quarter 2027. Stockholders' Equity slid to USD 8.4 million from USD 20.9 million, and a TTI-109 ulcerative colitis study is slated for 2027, depending on IND clearance and funding. Weighted-average shares were 9,381,344 last quarter, and the bottom-line loss was USD 6.5 million, versus Net Income of USD 4.2 million a year before.

Vistagen Therapeutics, Inc. (NASDAQ:VTGN): Estimate 0.37 Following PALISADE-4

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) is slated to publish second-quarter fiscal 2027 results, covering the period ended September 30, 2026, ahead of the opening bell on November 13, 2026, and no call time turned up in coverage. Analysts project a loss of USD 0.37 a share, a wider loss than the USD 0.30 in the preceding quarter, and the screener snapshot lists a valuation of USD 8.33 million, a nano-cap size. An implied price near USD 0.19 a share, worked out from 44.38 million shares, looks odd and is flagged. Revenue was USD 1.48 million compared with USD 244 thousand, mostly USD 1.2 million recognized once the Fuji Pharma exclusivity window lapsed, with an operating loss of USD 13.3 million. Vistagen Therapeutics, Inc. (NASDAQ:VTGN) had USD 16.99 million in cash plus USD 14.74 million in marketable securities, and it expects funding into 2027 though not beyond a year, and watched PALISADE-4 fall short of its main goal across the whole population. No numeric outlook turned up. R&D was USD 10.9 million compared with USD 11.7 million, G&A was USD 3.9 million compared with USD 4.4 million, with an accumulated Deficit of USD 490.35 million, versus stockholders' equity of USD 24.48 million.

Jaguar Health (NASDAQ:JAGX): An Unexplained Estimate of 614.25

Jaguar Health (NASDAQ:JAGX) is slated to publish third quarter 2026 results once trading ends on November 13, 2026. The screener snapshot puts the consensus at a loss of USD 614.25 a share, an extreme number with no explanation, reported only as the snapshot figure, compared with a USD 15.68 a share loss last quarter. The snapshot valuation is USD 6.44 million, a level bringing nano-cap risk and the lowest of the four. Last quarter's product revenue was USD 1.182 million compared with USD 2.936 million, operating losses reached USD 7.597 million while non-GAAP recurring EBITDA showed a loss of USD 8.381 million. Sales and Marketing spending dropped to roughly USD 5 thousand from USD 2.5 million once the sales team was dissolved on January 12, 2026. Jaguar Health (NASDAQ:JAGX) collected USD 16 million up front under the Future Pak and Woodward licensing agreement and expects the MVID clinical package before year-end 2026, although no numeric outlook, cash balance or Debt balance turned up in coverage. The agreement also delivered a USD 3 million payment for ending a buy-back, a USD 2 million holdback was described as collectible, with deferred revenue at USD 468 thousand, so reported results carry several one-off items.

Biofrontera Inc. (NASDAQ:BFRI): Estimate 0.11 and Revenue Growth

Biofrontera Inc. (NASDAQ:BFRI) is slated to publish third quarter 2026 results ahead of the opening bell on November 13, 2026. Analysts project a loss of USD 0.11 a share, wider than last quarter's loss of USD 0.05, and the screener snapshot lists a valuation of USD 13.92 million, a nano-cap size. The loss for six months was USD 0.44 a share compared with USD 1.05, and outside coverage placed the stock at USD 1.28 within a 52-week range of USD 0.55 to USD 1.40. Last quarter's product sales were USD 12.0 million, up 32.9%, gross Margin reached 80% and adjusted EBITDA was negative USD 0.2 million compared with negative USD 5.1 million. Biofrontera Inc. (NASDAQ:BFRI) had USD 4.7 million in cash versus USD 18.1 million in liabilities, while stockholders' equity stood at USD 6.0 million. No numeric outlook turned up, though management indicated Biofrontera is nearer to breakeven in 2026. SG&A dropped to USD 9.7 million from USD 10.6 million thanks to lower litigation fees, R&D dropped to USD 0.4 million from USD 0.9 million, and operating cash use over six months fell to USD 1.7 million from USD 7.2 million. The result of the September 28, 2026 PDUFA date did not surface.

Where Things Stand

For Canadian investors sizing up the group: Tvardi Therapeutics, Inc. (NASDAQ:TVRD) has a projected loss of 0.57 and USD 15.8 million in cash. Vistagen Therapeutics, Inc. (NASDAQ:VTGN) has a projected loss of 0.37 and USD 31.7 million in cash and securities. Jaguar Health (NASDAQ:JAGX) has an unexplained projected loss of 614.25 and a USD 6.44 million valuation. Biofrontera Inc. (NASDAQ:BFRI) has a projected loss of 0.11 and USD 4.7 million in cash. Tvardi, Vistagen and Biofrontera publish ahead of the open, whereas Jaguar Health publishes once trading ends. All four sit at nano-cap scale, so trading can dry up and prices can swing sharply. This piece is informational only.